Zilebesiran
Based on 1 Customer Validation
Zilebesiran (AD-85481; ALN-AGT) is a long-acting liver-targeted small interfering RNA (siRNA) antihypertensive agent. Zilebesiran binds to the hepatic asialoglycoprotein receptor (ASGPR), activates the RNA-induced silencing complex to degrade hepatic angiotensinogen mRNA, thereby inhibiting the gene expression and synthesis of angiotensinogen. Zilebesiran dose-dependently reduces serum angiotensinogen levels and 24-hour ambulatory blood pressure, with its effect persisting throughout the circadian cycle. Zilebesiran is applicable to research related to hypertension.
For research use only. We do not sell to patients.
- Purity : 95.59%
- CAS No.: 2380166-33-4
- Molecular Weight:16389.00
-
Storage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
All Angiotensin Receptor Isoforms
More
Biological Activity
Description
|
AGT |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2380166-33-4
-
Appearance Solid
-
Molecular Weight 16389.00
-
Color White to off-white
-
SMILES
[Zilebesiran]
-
Synonyms
AD-85481; ALN-AGT
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2242 KB)
References
[1]. Desai AS, et al. Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension. N Engl J Med. 2023;389(3):228-238. [Content Brief]
[2]. Dudzicz-Gojowy S, et al. Zilebesiran-Small Interfering RNAs as Prospective New Drug in the Treatment of Hypertension. J Clin Med. 2025;14(20):7365. Published 2025 Oct 17. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Zilebesiran
- 2380166-33-4
- AD-85481
- ALN-AGT
- AD85481
- AD 85481
- Small Interfering RNA (siRNA)
- Asialoglycoprotein Receptor (ASGPR)
- Angiotensin Receptor
- Asialoglycoprotein Receptor
- Ashwell-Morell Receptor
- 24-hour ambulatory blood pressure
- high-salt diet
- RNA-induced silencing complex
- hypertension
- hepatic asialoglycoprotein receptor
- angiotensinogen
- arterial hypertension
- angiotensinogen gene
- irbesartan
- hepatic angiotensinogen mRNA
- Inhibitor
- inhibitor
- inhibit